Nanotechnology Now - Press Release: Patent for the Novel Cancer Therapies

Home > Press > Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes

Abstract:
KN is pleased to announce that Penn State has been awarded a US Patent (8,747,891) for a highly unique cancer therapy. KN holds an exclusive license to this technology which builds on the work of Dr. Mark Kester of the University of Virginia. The inventing team includes: Mark Kester, Sriram Shanmugavelandy, and Todd Fox.

Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes

State College, PA | Posted on March 4th, 2015

This patent describes how Ceramide nano-scale liposomes can be loaded with a range of anti-cancer compounds and create a combination therapy that benefits from the therapeutic activity of both the Ceramide and the anti-cancer compound. Further, both are delivered in a nano-liposome which improves the delivery of the compounds by targeting the materials to tumors and by extending the time of biological activity (or therapeutic half-life).

Keystone Nano has conducted extensive preclinical testing on Ceramide Nanoliposomes and has submitted a Pre IND package to the US FDA. Keystone anticipates moving the Ceramide Nanoliposome program into human clinical testing in the near term. Keystone Nano's corporate partners have also contributed key support to the advancement of the technology.

Based in State College, Keystone Nano is working at the interface between nanotechnology and the life sciences and has licensed intellectual property around nanoparticles from Penn State University and is further developing this technology. The company is working to commercialize NanoJacket products and Nanoliposomes for a variety of medical applications.

####

For more information, please click here

Contacts:
Jeff Davidson, CEO
814-466-5080
Dr. Mylisa Parette
Research Manager
814-237-4657

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: